<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Meningitis MeG-CLS-028</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="meningitis">Meningitis</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<h2 id="meningitis-is-defined-as-inflammation-of-the-pia-and-arachnoid-meninges-and-the-cerebrospinal-fluid-csf-that-surrounds-the-brain-and-spinal-cord.-the-main-infectious-causes-are-viral-bacterial-and-fungal.">Meningitis is defined as inflammation of the pia and arachnoid meninges and the cerebrospinal fluid (CSF) that surrounds the brain and spinal cord. The main infectious causes are viral, bacterial and fungal. </h2>
<h2 id="meningitis-is-classified-clinically-as-either-acute-or-chronic.-acute-meningitis-occurs-within-hours-or-days-whereas-chronic-meningitis-evolves-over-weeks.-acute-meningitis-is-classified-as">Meningitis is classified clinically as either acute or chronic. Acute meningitis occurs within hours or days, whereas chronic meningitis evolves over weeks. Acute meningitis is classified as </h2>
<ul>
<li><h2 id="aseptic-which-is-mostly-viral-in-origin-or">aseptic (which is mostly viral in origin) or </h2></li>
<li><h2 id="septic-or-pyogenic-which-is-caused-by-bacteria.">septic or pyogenic which is caused by bacteria. </h2></li>
</ul>
<h2 id="chronic-meningitis-is-a-complex-entity-with-both-infectious-and-noninfectious-causes.">Chronic meningitis is a complex entity with both infectious and noninfectious causes.</h2>
<h3 id="target-users">Target users</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h3 id="target-area-of-use">Target area of use </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h3 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h3>
<p>This guideline addresses the management of the infective causes of meningitis in children and in adults. It provides advice on empirical antibiotic therapy.</p>
<p>The treatment of infective chronic meningitis has been added to this guideline and the management of meningitis in the immunocompromised has been adopted in this new version.</p>
<p>Antibiotic therapy is for two weeks at least.</p>
<h2 id="limitations">Limitations</h2>
<h2 id="none.">None.</h2>
<h2 id="pathogens">Pathogens</h2>
<p><strong>1) Bacterial:</strong></p>
<table>
<thead>
<tr class="header">
<th><strong>Age range</strong></th>
<th><strong>Organism</strong></th>
<th><strong>Site of entry</strong></th>
<th><strong>Predisposing conditions</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>All ages</td>
<td><em>Neisseria meningitidis</em></td>
<td>Nasopharynx</td>
<td>Usually none, rarely complement deficiency</td>
</tr>
<tr class="even">
<td>All ages</td>
<td><em>Streptococcus pneumoniae</em></td>
<td><p>Nasopharynx,</p>
<p>direct extension across skull fracture, or from contiguous or distant foci of infection</p></td>
<td>All conditions that predispose to pneumococcal bacteremia, fracture of cribriform plate, cochlear implants, cerebrospinal fluid otorrhea from basilar skull fracture, defects of the ear ossicle</td>
</tr>
<tr class="odd">
<td>All ages</td>
<td><em>Coagulase-negative staphylococci</em></td>
<td>Foreign body</td>
<td>Surgery and foreign body, especially ventricular drains</td>
</tr>
<tr class="even">
<td>All ages</td>
<td><em>Staphylococcus aureus</em></td>
<td>Bacteremia, foreign body, skin</td>
<td>Endocarditis, surgery and foreign body, especially ventricular drains; cellulitis, decubitus ulcer</td>
</tr>
<tr class="odd">
<td>Older adult (&gt;50yrs) and neonates</td>
<td><em>Listeria monocytogenes</em></td>
<td>Gastrointestinal tract, placenta</td>
<td>Glucocorticoids, Transplantation (especially renal transplantation), Pregnancy, Liver disease, Alcoholism, Malignancy</td>
</tr>
<tr class="even">
<td>Older adults and neonates</td>
<td><em>Gram-negative bacilli</em></td>
<td>Various</td>
<td>Advanced medical illness, neurosurgery, ventricular drains, disseminated strongyloidiasis</td>
</tr>
<tr class="odd">
<td>Adults; infants and children if not vaccinated</td>
<td><em>Haemophilus influenzae</em></td>
<td>Nasopharynx, contiguous spread from local infection</td>
<td>Diminished humoral immunity</td>
</tr>
</tbody>
</table>
<p><strong>2) Viral:</strong></p>
<p>A number of viruses produce aseptic meningitis including enteroviruses, herpes simplex virus (HSV), human immunodeficiency virus (HIV), West Nile virus, varicella-zoster virus, mumps, and lymphocytic choriomeningitis virus.</p>
<p><strong>3) Chronic meningitis:</strong></p>
<table>
<thead>
<tr class="header">
<th><strong>Age range</strong></th>
<th><strong>Organism</strong></th>
<th><strong>Site of entry</strong></th>
<th><strong>Predisposing conditions</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>All ages</td>
<td><span data-custom-style="Emphasis">Mycobacterium tuberculosis</span></td>
<td>Pulmonary TB</td>
<td><p>Acute complication of pulmonary TB or as a reactivation of extra pulmonary TB.</p>
<p>HIV significantly increases the risk.</p></td>
</tr>
<tr class="even">
<td>All ages</td>
<td><span data-custom-style="Emphasis">Cryptococcus neoformans</span></td>
<td></td>
<td>CD4 counts &lt; 100 cells/mm<sup>3</sup>.</td>
</tr>
</tbody>
</table>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>The main clinical features of acute bacterial meningitis (ABM) are headache, fever and meningism. When this triad is accompanied by alteration in consciousness or seizures, the diagnosis is usually not in doubt. Other symptoms include photophobia, nausea, vomiting, backache and lethargy. Progression occurs rapidly over 1-3 days but a smaller number may have an acute fulminant course lasting hours. However patients with HIV infection may present with only one or two of these main features.</p>
<p>TB Meningitis is a difficult condition to diagnose and confirm clinically. The clinical features are those of slowly progressive. Constitutional TB symptoms including fever, night sweats, weight loss and malaise may be present for a week or more early on but these may also be absent or are not specific for TB. The main neurological symptoms suggestive of TB meningitis are headache, nausea, vomiting, irritability, behaviour change and meningism of gradual onset usually for a period of one week or usually longer in adults. However, headaches may be less prominent in children, fever may be absent in 10-20% of adults and the signs of meningitis are generally less prominent as compared to acute bacterial meningitis.</p>
<h2 id="examination-findings">Examination findings</h2>
<h2 id="management">Management </h2>
<p><strong>Investigations</strong>:</p>
<p><strong>1) Blood culture</strong> are often positive and can be useful in the event that cerebrospinal fluid (CSF) cannot be obtained before the administration of antimicrobials. Approximately 50 to 90 percent of patients with bacterial meningitis have positive blood cultures.</p>
<p><strong>2) Lumbar puncture (LP)</strong> is the key investigation and is an overall simple and very safe test.</p>
<p>*CONTRAINDICATIONS- Increased intracranial pressure; Thrombocytopenia or other bleeding diathesis; Cardiopulmonary instability; Soft tissue infection at the puncture site.</p>
<table>
<thead>
<tr class="header">
<th></th>
<th><strong>Acute bacterial meningitis</strong></th>
<th><strong>Tuberculous</strong></th>
<th><strong>Cryptococcal</strong></th>
<th><strong>Viral</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Appearance</strong></td>
<td>cloudy, purulent</td>
<td>yellow/cloudy</td>
<td>clear/cloudy</td>
<td>Clear (cloudy)</td>
</tr>
<tr class="even">
<td><strong>Cell/mm<sup>3</sup></strong></td>
<td><p>high</p>
<p>&gt; 2000/mm<sup>3</sup></p>
<p>neutrophils</p></td>
<td><p>increased</p>
<p>50-500/mm<sup>3</sup></p>
<p>lymphocytes</p></td>
<td><p>normal/increased</p>
<p>0-100/mm<sup>3</sup></p>
<p>lymphocytes</p></td>
<td><p>normal/increased</p>
<p>0-500/mm<sup>3</sup></p>
<p>lymphocytes</p></td>
</tr>
<tr class="odd">
<td><p><strong>Glucose</strong></p>
<p><strong>(n=&gt; 50% of plasma level)</strong></p></td>
<td><p>very low/absent</p>
<p>&lt;1mmol/L</p></td>
<td>low</td>
<td>normal/low</td>
<td>normal</td>
</tr>
<tr class="even">
<td><p><strong>Protein</strong></p>
<p><strong>(n=&lt; 0.5 mg/l)</strong></p></td>
<td><p>elevated</p>
<p>1-2 mg/L</p></td>
<td><p>high/very high</p>
<p>1-5 mg/L</p></td>
<td><p>normal/elevated</p>
<p>0.5-2 mg/L</p></td>
<td><p>normal/elevated</p>
<p>0.5-1 mg/L</p></td>
</tr>
<tr class="odd">
<td><strong>Diagnosis confirmed</strong></td>
<td>Gram stain &amp; culture</td>
<td>ZN stain &amp; culture</td>
<td>India ink stain/ Cryptococcal Antigen/Culture</td>
<td>PCR</td>
</tr>
</tbody>
</table>
<p><strong>Treatment:</strong></p>
<p><strong>Bacterial</strong> — The mainstay of management of ABM is prompt diagnosis and early treatment with antimicrobials. It is important that antimicrobials should be given straight away (within 20-30 mins of first seeing the patient) and not to delay treatment because of ongoing investigations including a LP. In adults ceftriaxone is now the drug of first choice. In adult, the dose is 4g/day while in children, 100 <span data-custom-style="nowrap">mg/kg</span>/day IV (maximum dose 4 <span data-custom-style="nowrap">g/day)</span> in 1 or 2 divided doses. The use of steroids in the treatment of ABM in adults is currently not recommended in Africa.</p>
<p><strong>Viral</strong> — Most patients with viral meningitis require only supportive care. Patients who are elderly, immunocompromised, or have received antibiotics prior to presentation may be considered for empiric antibacterial therapy for 48 hours, even if viral meningitis is the suspected diagnosis.</p>
<p>If HIV is a diagnostic consideration, then blood testing for HIV RNA and HIV antibody should be performed.</p>
<p>If aseptic meningitis due to HSV is suspected, empiric therapy with intravenous acyclovir (for adult and children: 10-15 mg/kg every 8 hours, for neonates: 60 mg/kg per day divided every 8 hours) can be considered for hospitalized patients.</p>
<p><strong>TB</strong> — All four TB drugs are given for the first 2 months after which isoniazid and rifampicin are continued usually for another 10 months. In practice the standard total period of treatment is 12 months for tuberculous meningitis and longer for tuberculoma.</p>
<p>In general, glucocorticoid therapy is warranted for all patients (including those with HIV) with convincing epidemiologic or clinical evidence for tuberculous meningitis. The regimen consists of oral prednisolone: children: 2 to 4 <span data-custom-style="nowrap">mg/kg</span> per day; adolescents and adults: 60 <span data-custom-style="nowrap">mg/day</span>. Administer initial dose for two weeks, then taper gradually over the next six weeks (ie, reduce daily dose by 10 mg each week); total duration is approximately eight weeks.</p>
<p>Starting ART is recommended after the first 2 weeks of TB meningitis treatment in HIV.</p>
<p><strong>Cryptococcal</strong> — The treatment of Cryptococcal meningitis (CM) in Africa is mostly based on fluconazole alone. There are three phases: induction phase, consolidation phase and maintenance phase. In the induction phase, fluconazole (1200 mg orally per day) may be administered for at least 10 weeks or until CSF culture results are negative, followed by consolidation therapy with fluconazole (400 mg orally daily). The maintenance or prophylaxis phase uses fluconazole 200 mg daily until the CD4 count is &gt; 200/mm<sup>3</sup> for &gt;6 months. Multiple lumbar punctures may be needed to relieve raised ICP.</p>
<p>A delay in initiation of ART until at least 4 weeks after the start of the treatment phase appears to have a better outcome in fluconazole treated patients. Long-term mortality in CM is high (&gt; 50%) even with ART.</p>
<p><strong>Unclear etiology</strong> — When it is not clear whether the patient has a viral or bacterial process, we recommend empirical antibiotics after obtaining blood and CSF cultures or observation with repeat lumbar puncture in 6 to 24 hours. If the patient is symptomatically improved and culture results are negative, then antibiotics can generally be stopped without a repeat LP. However, repeat LPs may be indicated in patients with persistent symptoms who do not have a clear diagnosis.</p>
<table>
<thead>
<tr class="header">
<th></th>
<th><strong>Acute bacterial meningitis</strong></th>
<th><strong>Tuberculous</strong></th>
<th><strong>Cryptococcal</strong></th>
<th><strong>HSV</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><strong>Medication dose</strong></p>
<p><strong>(<em>in children</em>)</strong></p></td>
<td><p>Ceftriaxone</p>
<p>4 g <em>(100 mg/kg</em>) OD</p></td>
<td><p><sup>1)</sup>TB4</p>
<p><sup>2)</sup>Prednisolone<br />
60 mg <em>(2-4 mg/kg)</em> OD</p></td>
<td><p>Fluconazole</p>
<p><sup>1)</sup>1200 mg <em>(18 mg/kg)</em> OD</p>
<p><sup>2)</sup>400 mg <em>(6 mg/k</em>g) OD</p>
<p><sup>3)</sup>200 mg <em>(3 mg/kg)</em> OD</p></td>
<td><p>Acyclovir</p>
<p>10-15 mg/kg TDS</p>
<p><em>(neonate: 60 mg/kg divided every 8 hours</em>)</p></td>
</tr>
<tr class="even">
<td><p><strong>Duration</strong></p>
<p><strong>(<em>in children</em>)</strong></p></td>
<td><p>2 weeks</p>
<p><em>(3 weeks)</em></p></td>
<td><p><sup>1)</sup> 12 months</p>
<p><sup>2)</sup> 2 weeks, then taper gradually over the next six weeks</p></td>
<td><p><sup>1)</sup>10 weeks</p>
<p><sup>2)</sup>8 weeks</p>
<p><sup>3)</sup>until the CD4 count is &gt;200/mm3 for &gt; 6 months</p></td>
<td>2 weeks</td>
</tr>
</tbody>
</table>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><h2 id="deterioration-in-clinical-status-can-occur-rapidly-so-frequently-assess-the-patients-neurologic-status-especially-level-of-consciousness-and-vital-signs.-report-new-focal-signs-immediately.">Deterioration in clinical status can occur rapidly, so frequently assess the patient&#39;s neurologic status, especially level of consciousness and vital signs. Report new focal signs immediately.</h2></li>
<li><h2 id="try-to-minimize-increases-in-the-patients-icp.-appropriate-measures-may-include-keeping-the-patients-head-of-bed-elevated-to-30-degrees-keeping-the-head-midline-minimizing-suctioning-using-sedation-keeping-the-room-quiet-and-dark-and-avoiding-hypercapnia.">Try to minimize increases in the patient&#39;s ICP. Appropriate measures may include keeping the patient&#39;s head of bed elevated to 30 degrees, keeping the head midline, minimizing suctioning, using sedation, keeping the room quiet and dark, and avoiding hypercapnia.</h2></li>
<li><h2 id="patients-with-bacterial-meningitis-may-develop-dehydration-shock-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone-andor-intracranial-hypertension.-closely-monitor-for-fluid-and-electrolyte-imbalances.">Patients with bacterial meningitis may develop dehydration, shock, syndrome of inappropriate secretion of antidiuretic hormone, and/or intracranial hypertension. Closely monitor for fluid and electrolyte imbalances.</h2></li>
<li><h2 id="analgesics-may-be-required-to-treat-headache.-darkening-the-room-may-help-if-the-patient-complains-of-photophobia.">Analgesics may be required to treat headache. Darkening the room may help if the patient complains of photophobia. </h2></li>
<li><h2 id="the-patients-hearing-should-be-assessed-before-discharge-because-hearing-loss-is-a-common-late-complication-of-bacterial-meningitis.">The patient&#39;s hearing should be assessed before discharge because hearing loss is a common late complication of bacterial meningitis.</h2></li>
<li><h2 id="keep-in-mind-that-because-n.-meningitidis-is-easily-spread-from-person-to-person-secondary-cases-need-to-be-prevented.-suspected-meningococcal-disease-should-be-reported-to-the-local-public-health-department.-people-in-close-contact-with-an-infected-person-should-receive-chemoprophylaxis-with-single-dose-of-oral-ciprofloxacin-500-mg-daily-adults-only-or-oral-rifampicin-10-mgkg-twice-daily-up-to-1200-mgday-for-4-days">Keep in mind that because <em>N. meningitidis</em> is easily spread from person to person, secondary cases need to be prevented. Suspected meningococcal disease should be reported to the local public health department. People in close contact with an infected person should receive chemoprophylaxis with single dose of oral ciprofloxacin 500 mg daily (adults only) or oral rifampicin 10 mg/kg twice daily (up to 1200 mg/day) for 4 days </h2></li>
</ul>
<h2 id="references">References</h2>
<p>NEUROLOGY IN AFRICA; William Howlett: Updated Oct 17,.2018 (First published: Aug 16, 2012)</p>
<p>Up To Date: Central nervous system tuberculosis: last updated: Oct 26, 2018.</p>
<p>Up To Date: Epidemiology of bacterial meningitis in adults: last updated: Sep 26, 2018.</p>
<p>Up To Date: Lumbar puncture: Indications, contraindications, technique, and complications: last updated: Sep 26, 2018.</p>
<p>Up To Date: Fluconazole: Drug information</p>
<p>Up To Date: Aseptic meningitis in adults: last updated: Sep 26, 2018.</p>
<p>Up To Date: Clinical features and diagnosis of acute bacterial meningitis: This topic last updated: Aug 30, 2018</p>
<p>Fire up to beat the threat of bacterial meningitis; Miller A, Nursing2013: December 2013 - Volume 43 - Issue 12 - p 52,58–58</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Eriko Ikeda</th>
<th>Date: 29 October 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 07 November 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="even">
<td>2.0</td>
<td>Rewritten to include the management of chronic meningitis and adapted to the new template</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>Review Comments (if applicable)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
